Vaccitech has established partnerships with leading institutions to support the development of its programs.
Vaccitech is seeking a partner to commercialize its lead program for universal influenza A and is also open to collaborating on its platform and other programs.
We have also entered into non-exclusive licensure of our T cell induction platform in oncology, and are committed to advancing the use of our platform for oncology in combination with checkpoint inhibitors.
Ludwig Cancer Research is an international community of distinguished scientists dedicated to preventing and controlling cancer. American businessman Daniel K. Ludwig began to support cancer research with the establishment of the Ludwig Institute for Cancer Research in 1971. Today, the scientific efforts endowed through his resources have grown to encompass the Ludwig Institute and the Ludwig Centers and professorships at six U.S. institutions.